Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Alexander K TsaiSana KagalwallaJenna LangerThuy Le-KumarVikas Le-KumarEmmanuel S AntonarakisPublished in: Expert opinion on biological therapy (2024)
Pembrolizumab has not benefitted unselected metastatic prostate cancer patients when combined with chemotherapy, next-generation hormonal agents (NHA), or poly (ADP-ribose) polymerase inhibitors (PARPi). PD-L1 positivity does not predict response to pembrolizumab in this disease. A small number of responding patients can likely be explained by rare genetic and molecular defects, and more innovative combination strategies are needed to improve outcomes in prostate cancer patients who are not sensitive to pembrolizumab. Emphasis should be placed on developing additional or alternative immuno-oncology approaches beyond classical immune checkpoint inhibition.
Keyphrases
- prostate cancer
- advanced non small cell lung cancer
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- ejection fraction
- radical prostatectomy
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- genome wide
- copy number
- gene expression
- patient reported outcomes
- radiation therapy
- skeletal muscle
- structural basis